Afanat (Afatinib) 30/40 mg 28 tab

Name: Buy Afanat (Afatinib) 30 mg / 40 mg
Price: 160.0 EUR
Availability: InStock

160,00 €

Дозировка

Пожалуйста, выберите

Lung cancer treatment, oncology

В наличии

Сохранить этот товар, чтобы посмотреть позже

Отзывы покупателей

Отзывы только от проверенных покупателей

Отзывов пока нет. Вы можете приобрести этот товар и стать первым, кто оставит отзыв.

Afanat (Afatinib) 30/40 mg 28 tab

Сведения о товаре

Afanat (Afatinib) 30/40 mg

Manufacturer: Natco Pharma India

Pack size: 28 tablets

Afatinib (Afatinib) is an anticancer drug belonging to the EGFR/HER2/HER4 tyrosine kinase inhibitor class. It is used to treat non-small cell lung cancer (NSCLC) with certain mutations in the EGFR genes. The drug blocks signaling pathways that promote tumor cell growth and proliferation, helping to slow disease progression.

Dosage form and composition

Film-coated tablets, 30 mg or 40 mg Afatinib.

Excipients: (lactose, microcrystalline cellulose, crospovidone, magnesium stearate, etc.)

Показания

Non-small cell lung cancer (NSCLC) with EGFR mutations (particularly sensitive to inhibition)

Can be used as primary therapy for advanced disease or after failure of other EGFR inhibitors, depending on the patient's condition and mutation analysis results.

Дозировка и способ применения

Take once daily, preferably on an empty stomach: 1 hour before or 2 hours after meals.

40 mg is the standard starting dose for most adults without severe renal or hepatic impairment.

In patients with renal or hepatic impairment, or if the drug is poorly tolerated, dosage adjustments may be necessary as prescribed by a physician.

Побочные эффекты

The most common are:

Diarrhea (may be severe)

Rash, skin redness, dry skin

Nausea, vomiting, decreased appetite

Dry mucous membranes, stomatitis (inflammation of the oral mucosa)

Nail disorders, itching

Противопоказания

Allergy to afatinib or any of the excipients.

Severe liver or kidney impairment, if safe administration cannot be ensured.

Pregnancy and breastfeeding - the drug may be harmful to the fetus/child.

Not intended for use in children, as safety and efficacy have not been established.

Меры предосторожности

Determination of EGFR mutation status is mandatory before initiating therapy.

Regular monitoring of liver, kidney function, electrolytes, skin, and possible manifestations of pulmonary toxicity is necessary. Avoid combination with strong inhibitors or inducers that affect metabolism via CYP systems if this causes interactions.

Задайте вопрос или уточните условия доставки в вашу страну

Telegram

WhatsApp